Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for MIBC
NCT04630730Phase 2Active, not recruiting
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Jun 2022
- Primary completion
- Apr 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in bladder cancer, sponsored by Swiss Group for Clinical Cancer Research. Primary endpoint: Pathological complete remission. Started Jun 2022; status: active, not recruiting.
02
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT04630730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04630730.